Showing results (91-100 of 409) with videos related to

Sort By:
Pageof 41
Molecular Therapy. Oncology|April 18, 2025
Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trialHamenth Kumar Palani, Arun Kumar Arunachalam, Uday Kulkarni, et al.
Molecular Therapy. Oncology|April 15, 2025
Erratum: Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapyWei Ni, Swati Garg, Basudev Chowdhury, et al.
Molecular Therapy. Oncology|April 1, 2025
Engineering a novel HSV-1 strain for oncolytic therapy of solid tumorsKarina Vázquez-Arreguín, Alex Gonzalez, Amy Webb, et al.
Molecular Therapy. Oncology|June 16, 2025
Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagementErika A K Fletcher, Robert A Cordfunke, Aikaterini Nasi, et al.
Molecular Therapy. Oncology|June 16, 2025
Real-time imaging reveals radiation-induced intratumor apoptosis via nutrient and oxygen deprivation following vascular damageGo Kagiya, Ryohei Ogawa, Toshihide Matsumoto, et al.
Molecular Therapy. Oncology|May 7, 2025
Characterization of a multiplex digital PCR assay to quantify total T cells relative to chimeric antigen receptor-positive T cellsLindsey A Murphy, Laura Sedivy, M Eric Kohler, et al.
Molecular Therapy. Oncology|February 3, 2026
Improved oncolytic and immunostimulatory activity of the spontaneous jin-3 reovirus mutant in preclinical bladder cancer modelsArjanneke F van de Merbel, Maaike H van der Mark, Lobke C M Hensen, et al.
Molecular Therapy. Oncology|February 2, 2026
Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cellsJuliane Mietz, Lukas Egli, Meike Misiune, et al.
Molecular Therapy. Oncology|February 2, 2026
Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effectsManikandan Santhanam, Venkatadri Babu, Anna Shteinfer-Kuzmine, et al.
Molecular Therapy. Oncology|February 3, 2026
An attenuated coxsackievirus B5 mutant carrying VP1-N157K retains oncolytic potency against non-small cell lung cancerLifang Song, Bopei Cui, Qiushuang Gao, et al.
Pageof 41